493035-81-7

Prostaglandin E₂ (PGE₂; ) activates four E prostanoid (EP) receptors, EP_1-4. EP₄ is a G protein-coupled receptor that, by elevating the second messenger cAMP, plays important roles in bone formation and resorption, cancer, and atherosclerosis. CAY10684 is a lactam that acts as a potent EP₄ agonist, triggering cAMP signaling with an EC₅₀ value of 0.8 nM. It displays more than 1,000-fold selectivity for EP₄ over other EP receptors.

(2R)-2-[(1E)-3-(4''-Chloro-2''-methyl[1,1''-biphenyl]-3-yl)-3-hydroxy-1-propen-1-yl]-5-oxo-1-pyrrolidineheptanoic Acid is an EP4 receptor agonist.

EP4: 0.8 nM (EC₅₀); EP2: >100000 nM (Ki); EP3: 38000 nM (Ki); EP4: 3.1 nM (Ki)

[1] YONG S. CHYUN  Lawrence G R. Stimulation of bone formation by prostaglandin E2[J]. Prostaglandins, 1984, 27 1: Pages 97-103. DOI: 10.1016/0090-6980(84)90223-5
[2] G HAWCROFT  M A H  C W S Ko. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells[J]. Oncogene, 2006, 26 21: 3006-3019. DOI: 10.1038/sj.onc.1210113
[3] VLADIMIR R BABAEV. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis.[J]. Cell metabolism, 2008: 492-501. DOI: 10.1016/j.cmet.2008.09.005
[4] TODD R. ELWORTHY  et al. et al. Lactams as EP4 Prostanoid Receptor Subtype Selective Agonists. Part 1. 2-Pyrrolidinones — Stereochemical and Lower Side-Chain Optimization.[J]. ChemInform, 2004, 35 34. DOI: 10.1002/chin.200434228